Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
FDA Approves First Oral Blood Thinning Medication for Children
FDA Approves First Oral Blood Thinning Medication for ChildrenToday, the U.
U.S. Supreme Court rebuffs AbbVie appeal in patent fight involving AndroGel drug
WASHINGTON (Reuters) - The U.
After FDA rejection, EU says yes to Sanofi’s Aubagio in kids with MS
Sanofi’s Aubagio has become the first oral therapy approved for first-line use in children and adolescents with multiple sclerosis in the EU, a few days after the same indication was turned down by ...
Pfizer’s JAK inhibitor Xeljanz shows benefit in COVID-19 pneumonia
Pfizer’s JAK inhibitor Xeljanz reduced the risk of severe outcomes in hospitalised adult patients with COVID-19 pneumonia who were not on ventilation, according to new study data.
FDA Approves Astepro® Allergy Nasal Spray for Over-the-Counter Use in the United States
WHIPPANY, N.
Chinese patent reforms to bolster pharma innovation
Market research suggests the new drug patent reforms in China, in addition to other regulatory changes, will incentivise innovative pharma research.
Bristol-Myers, Eisai in up to $3.1 Billion Deal to Develop Cancer Drug Candidate
Bristol-Myers Squibb Co and Eisai Co said on Thursday they had entered into an agreement worth up to $3.
Biogen shelves gosuranemab after no benefit seen in Phase II Alzheimer's study
Biogen said Wednesday that it is ending development of the investigational anti-tau antibody gosuranemab after it missed the primary efficacy endpoint of the Phase II TANGO trial in patients with earl...
EQT Private Equity to sell Aldevron to Danaher Corporation for enterprise value of USD 9.6 billion
EQT is pleased to announce that the EQT VIII fund (“EQT Private Equity”) has agreed to sell Aldevron to Danaher Corporation for an enterprise value of USD 9.
Health chiefs recall dozens of batches of common blood pressure pills because they contain 'world's most explosive chemical' which also causes cancer
Health chiefs today recalled dozens of batches of blood pressure pills because they were found to contain an explosive chemical.
Horizon Therapeutics plc Announces Purchase of Manufacturing Facility to Support Growth of On-Market Rare Disease and Pipeline Biologics
DUBLIN--(BUSINESS WIRE)--Jun.
Boehringer, Lilly and Takeda join matchmaker PharmStars' digital health accelerator
Just weeks after its debut, the PharmStars digital health accelerator nabbed its first pharma members—Boehringer Ingelheim, Eli Lilly and Takeda.
220
221
222
223
224
225
226
227
228
